Valvulopatía mitral y tricuspídea

  1. Martínez Monzonís, Amparo
  2. Abu Assi, Emad
  3. Raposeiras Roubín, Sergio
  4. Vega Fernández, J. M.
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2013

Series: 11

Issue: 41

Pages: 2456-2464

Type: Article

DOI: 10.1016/S0304-5412(13)70646-2 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Sustainable development goals

Abstract

Mitral valve disease epidemiology and treatment have changed significantly in recent years. Mitral valve insufficiency is the second leading cause of valvulopathy in the Western world. The most common etiologies are degenerative and ischemic disease. In the Western world, mitral stenosis has become less common and the most cases are rheumatic in origin. Echocardiogram is imaging technique of choice in the diagnosis and follow-up of both entities. Surgery remains the most common treatment modality for mitral valve disease although there has been an increasing trend towards mitral valve repair. Percutaneous mitral valvuloplasty continues playing an important role in the management of subsidiary patients for receiving treatment. Percutaneous mitral valve repair using the MitraClip system has been developed although currently its indications are very restricted.

Bibliographic References

  • Badano LP, Agricola E, Pérez de Isla L, Gianfagna P, Zamorano JL. Evaluation of the tricuspid valve morphology and function by transthoracic real time three dimensional echocardiography. Eur J Echocardiogr. 2009;10(4):477-84.
  • Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009;22(1):1-23.
  • Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients withvalvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008; 118(15):e523-661.
  • Chandrashekhar Y, Westaby S, Narula J. Mitral stenosis. Lancet. 2009; 374(9697):1271-83.
  • Di Mauro M, Bezante GP, Di Baldassarre A, Clemente D, Cardinali A, Acitelli A. Functional tricuspid regurgitation: An underestimated issue. Int J Cardiol. En prensa 2013.
  • Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet. 2009;373(9672):1382-94.
  • Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. En prensa 2013.
  • Shinn SH, Schaff HV. Evidence based surgical management of acquired tricuspid valve disease. Nat Rev Cardiol. 2013;10(4):190-203.
  • Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33(19):2451-96.
  • Whitlow PL, Feldman T, Pedersen WR, Lim DS, Kipperman R, Smalling R. Acute and 12 month results with catheter based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge to Edge Repair) High Risk Study. J Am Coll Cardiol. 2012; 59(2):130-9.
Data source: Dialnet